BAX Valuation Metrics
BAX Stock Price Metrics
BAX Dividend Metrics
BAX Growth Rate Metrics
BAX Discounted Cash Flow Metrics
| Fair Value Price | - |
| Margin of Safety | - |
BAX Revenue Metrics
BAX PE Ratio Metrics
| PE Ratio | 157.29 |
| PE Ratio Avg TTM | 44.53 |
| PE Ratio Avg 3Y | 34.41 |
| Current VS TTM Avg | +253.22% |
| Current VS 3Y Avg | +357.15% |
| Current VS 5Y Avg | +320.21% |
BAX PS Ratio Metrics
| PS Ratio | 0.93 |
| PS Ratio Avg TTM | 1.00 |
| PS Ratio Avg 3Y | 1.30 |
| Current VS TTM Avg | -6.90% |
| Current VS 3Y Avg | -28.72% |
| Current VS 5Y Avg | -48.32% |
BAX PB Ratio Metrics
| PB Ratio | 1.75 |
| PB Ratio Avg TTM | 1.60 |
| PB Ratio Avg 3Y | 2.25 |
| Current VS TTM Avg | +9.35% |
| Current VS 3Y Avg | -22.12% |
| Current VS 5Y Avg | -42.46% |
BAX Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 14.78 |
| PFCF Ratio Avg TTM | 39.86 |
| PFCF Ratio Avg 3Y | 31.02 |
| Current VS TTM Avg | -62.92% |
| Current VS 3Y Avg | -52.35% |
| Current VS 5Y Avg | -51.24% |
BAX Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 1.63 |
| Debt/Equity Ratio Avg TTM | 1.78 |
| Debt/Equity Ratio Avg 3Y | 2.05 |
| Current VS TTM Avg | -8.43% |
| Current VS 3Y Avg | -20.39% |
| Current VS 5Y Avg | -11.01% |
BAX PEG Ratio Metrics
| PEG Ratio | - |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | - |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | - |
| Current VS 5Y Avg | - |
BAX FCF Yield
| FCF Yield | 6.77% |
| FCF Yield Avg TTM | 3.16% |
| FCF Yield Avg 3Y | 3.91% |
| Current VS TTM Avg | +114.33% |
| Current VS 3Y Avg | +72.93% |
| Current VS 5Y Avg | +81.19% |
BAX Earnings Yield
| Earnings Yield | 0.64% |
| Earnings Yield Avg TTM | 10.19% |
| Earnings Yield Avg 3Y | 8.29% |
| Current VS TTM Avg | -93.72% |
| Current VS 3Y Avg | -92.28% |
| Current VS 5Y Avg | -88.09% |
BAX EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 1943.16 |
| Ev/Ebit Ratio Avg TTM | 442.63 |
| Ev/Ebit Ratio Avg 3Y | 243.35 |
| Current VS TTM Avg | +339.01% |
| Current VS 3Y Avg | +698.50% |
| Current VS 5Y Avg | +1346.78% |
BAX EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 24.69 |
| Ev/Ebitda Ratio Avg TTM | 20.33 |
| Ev/Ebitda Ratio Avg 3Y | 19.11 |
| Current VS TTM Avg | +21.42% |
| Current VS 3Y Avg | +29.19% |
| Current VS 5Y Avg | +29.22% |
BAX EV/Assets Ratio Metrics
| Ev/Assets Ratio | 0.92 |
| Ev/Assets Ratio Avg TTM | 0.91 |
| Ev/Assets Ratio Avg 3Y | 1.05 |
| Current VS TTM Avg | +0.99% |
| Current VS 3Y Avg | -12.13% |
| Current VS 5Y Avg | -30.41% |
BAX EV/Sales Ratio Metrics
| Ev/Sales Ratio | 1.61 |
| Ev/Sales Ratio Avg TTM | 1.72 |
| Ev/Sales Ratio Avg 3Y | 2.17 |
| Current VS TTM Avg | -6.29% |
| Current VS 3Y Avg | -25.76% |
| Current VS 5Y Avg | -39.02% |
BAX Current Ratio Metrics
| Current Ratio | 2.31 |
| Current Ratio Avg TTM | 1.83 |
| Current Ratio Avg 3Y | 1.71 |
| Current VS TTM Avg | +25.89% |
| Current VS 3Y Avg | +35.09% |
| Current VS 5Y Avg | +21.05% |
BAX Quick Ratio Metrics
| Quick Ratio | 1.56 |
| Quick Ratio Avg TTM | 1.31 |
| Quick Ratio Avg 3Y | 1.23 |
| Current VS TTM Avg | +19.54% |
| Current VS 3Y Avg | +27.09% |
| Current VS 5Y Avg | +11.69% |
BAX ROIC Metrics
| ROIC | (1.79%) |
| ROIC Avg 3Y | (2.61%) |
| ROIC Avg 5Y | 0.30% |
| Current VS 3Y Avg | -31.48% |
| Current VS 5Y Avg | -696.67% |
| Current VS 10Y Avg | -151.72% |
BAX Return on Assets Metrics
| ROA | (4.77) |
| ROA Avg TTM | (3.64) |
| ROA Avg 3Y | (1.62) |
| Current VS TTM Avg | +30.86% |
| Current VS 3Y Avg | +193.54% |
| Current VS 5Y Avg | -1111.31% |
BAX Return on Equity Metrics
| ROE | (15.61) |
| ROE Avg TTM | (12.46) |
| ROE Avg 3Y | (8.76) |
| Current VS TTM Avg | +25.23% |
| Current VS 3Y Avg | +78.25% |
| Current VS 5Y Avg | +1042.20% |
BAX Net Profit Margin Metrics
| Net Profit Margin | (8.51%) |
| Net Profit Margin Avg TTM | (7.30%) |
| Net Profit Margin Avg 3Y | (3.29%) |
| Current VS TTM Avg | +16.50% |
| Current VS 3Y Avg | +158.66% |
| Current VS 5Y Avg | -845.40% |
Last Updated: Thursday, June 11, 2026
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider